Mesa Laboratories (MLAB) Projected to Release Quarterly Earnings on Monday

Mesa Laboratories (NASDAQ:MLAB) is anticipated to post its Q1 2027 results after the market closes on Monday, August 10th. Analysts expect the company to announce earnings of $2.63 per share and revenue of $60.8670 million for the quarter. Investors may visit the the company’s upcoming Q1 2027 earning report page for the latest details on the call scheduled for Monday, August 10, 2026 at 4:30 PM ET.

Mesa Laboratories (NASDAQ:MLAB) last posted its earnings results on Wednesday, May 27th. The medical instruments supplier reported $1.53 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.78 by ($0.25). The business had revenue of $63.72 million during the quarter, compared to analyst estimates of $65.21 million. Mesa Laboratories had a net margin of 2.69% and a return on equity of 20.96%. During the same quarter last year, the firm earned ($1.31) earnings per share.

Mesa Laboratories Stock Up 1.6%

Mesa Laboratories stock opened at $102.65 on Friday. The company has a market capitalization of $574.84 million, a P/E ratio of 85.54 and a beta of 0.92. Mesa Laboratories has a 1-year low of $58.83 and a 1-year high of $113.99. The company has a current ratio of 1.72, a quick ratio of 1.29 and a debt-to-equity ratio of 0.78. The firm’s fifty day simple moving average is $100.33 and its 200-day simple moving average is $95.15.

Mesa Laboratories Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 15th. Investors of record on Monday, August 31st will be issued a dividend of $0.16 per share. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date is Monday, August 31st. Mesa Laboratories’s dividend payout ratio (DPR) is presently 53.33%.

Insider Transactions at Mesa Laboratories

In other Mesa Laboratories news, CFO John Sakys sold 2,827 shares of the business’s stock in a transaction dated Monday, June 22nd. The shares were sold at an average price of $89.50, for a total transaction of $253,016.50. Following the sale, the chief financial officer directly owned 19,785 shares of the company’s stock, valued at $1,770,757.50. The trade was a 12.50% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, SVP Brian David Archbold sold 2,516 shares of the stock in a transaction dated Monday, June 22nd. The stock was sold at an average price of $89.50, for a total transaction of $225,182.00. Following the transaction, the senior vice president owned 6,377 shares of the company’s stock, valued at approximately $570,741.50. This represents a 28.29% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 8,277 shares of company stock valued at $770,122 over the last 90 days. 2.80% of the stock is owned by corporate insiders.

Institutional Trading of Mesa Laboratories

Several institutional investors and hedge funds have recently bought and sold shares of MLAB. Invesco Ltd. grew its stake in Mesa Laboratories by 11.7% in the fourth quarter. Invesco Ltd. now owns 12,845 shares of the medical instruments supplier’s stock valued at $1,008,000 after purchasing an additional 1,350 shares in the last quarter. XTX Topco Ltd bought a new stake in shares of Mesa Laboratories during the 4th quarter worth approximately $989,000. Tudor Investment Corp ET AL boosted its holdings in shares of Mesa Laboratories by 332.5% in the 4th quarter. Tudor Investment Corp ET AL now owns 27,426 shares of the medical instruments supplier’s stock valued at $2,153,000 after buying an additional 21,085 shares during the last quarter. Quadrature Capital Ltd bought a new position in shares of Mesa Laboratories in the fourth quarter valued at $1,062,000. Finally, Numerai GP LLC grew its stake in shares of Mesa Laboratories by 313.0% in the fourth quarter. Numerai GP LLC now owns 14,909 shares of the medical instruments supplier’s stock valued at $1,170,000 after buying an additional 11,299 shares in the last quarter. Institutional investors own 90.60% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings cut shares of Mesa Laboratories from a “sell (d+)” rating to a “sell (d)” rating in a research report on Wednesday, June 3rd. Two investment analysts have rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Reduce” and a consensus price target of $94.00.

Mesa Laboratories Company Profile

Mesa Laboratories, Inc (NASDAQ: MLAB) is a global provider of instrumentation products designed for critical process monitoring, testing and calibration. Headquartered in Lakewood, Colorado, the company serves a diverse set of end markets including healthcare, pharmaceutical, food and beverage, energy and industrial sectors. With a focus on precision measurement and validation, Mesa Laboratories helps customers ensure regulatory compliance, product safety and operational efficiency across complex manufacturing and sterilization processes.

The company’s product portfolio encompasses biological and chemical indicators for sterilization process validation, digital data loggers and sensors for environmental monitoring, and optical gas analyzers with sample-conditioning solutions for oil, gas and petrochemical applications.